NCT03472378View on ClinicalTrials.gov

Can DFN-15 Terminate Migraine With Allodynia?

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

April 12, 2019

Study Completion Date

April 12, 2019

Conditions
Migraine With AuraMigraine Without AuraAllodynia
Interventions
DRUG

DFN-15

Oral Solution of 4.8 mL containing 120 mg of DFN-15

OTHER

Placebo

Oral Solution of 4.8 mL containing 0 mg of DFN-15

Trial Locations (1)

06107

Hartford HealthCare Headache Center, West Hartford

Sponsors
All Listed Sponsors
collaborator

Rami Burstein, PhD, Beth Israel Deaconess Medical Center

UNKNOWN

collaborator

Dr. Reddy's Laboratories Limited

INDUSTRY

lead

Hartford Hospital

OTHER